Loading
companiesCompany
ECOG-ACRIN Cancer Research Group
US cooperative group that pairs a therapy group with an imaging group; its E1910 trial moved blinatumomab into frontline leukaemia treatment.
Also called: ECOG-ACRINEastern Cooperative Oncology GroupECOGAmerican College of Radiology Imaging NetworkACRIN
Overview
Merger (2012) of the Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network. E1910 showed adding blinatumomab consolidation improves survival in MRD-negative B-ALL, leading to the 2024 label. Also runs TMIST (tomosynthesis vs digital mammography screening) and the ECOG performance status scale.
Headquarters
Philadelphia, PA, US
Scorecard
All companies#103of 1244 companies, score 50
- approved products +6
- targets +4
- modalities +4
- regions +6
- registry trials +30
1 approved, 0 in phase 3, 0 earlier, 2 targets, 2,302 registry studies. Formula on the scorecards page.
Website
Founded
2012
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-01.
Matched to ECOG-ACRIN Cancer Research Group, including child institutions. 2 works · 7 citations · 50% open access · 50% clinical trials · 0% reviews.
Oncology works per year
02022
12023
02024
02025
12026
Most works
- Mohammed Al‐Jumayli1 works
- Carolyn Jean Presley1 works
- Paul J. Novotny1 works
- Julie Renee Brahmer1 works
- Joleen Marie Hubbard1 works
- Steven R. Alberts1 works
- Megan Ann Baumgart1 works
- Apar Kishor Ganti1 works
- Stephen K. Williamson1 works
- Melissa A. Simon1 works
Most cited
| Work | Journal | Year | Citations |
|---|---|---|---|
| Baseline Quality of Life is a Strong and Independent Prognostic Factor for Overall Survival in Metastatic Colorectal Cancer 10.1177/10732748231185047 · open access | Cancer Control | 2023 | 7 |
| A randomized phase III trial of chemo-immunotherapy vs immunotherapy alone for the vulnerable older adult with advanced non–small cell lung cancer: The ACHIEVE study—ECOG-ACRIN EA5221. conference abstract · 10.1200/jco.2026.44.16_suppl.tps8674 | Journal of Clinical Oncology | 2026 | 0 |
EstablishedOral cytotoxic regimen
CAPTEM (capecitabine plus temozolomide) is an all-oral chemotherapy pair that shrinks pancreatic neuroendocrine tumours in about a third of patients.
Mark R. Litzow
Professor of Medicine, Mayo Clinic; Chair, ECOG-ACRIN Leukemia Committee; Study Chair, E1910
Acute lymphoblastic leukaemiaImmunotherapyTransplant
Leukaemia specialist who led E1910, the trial that put blinatumomab into frontline treatment for adults in remission.
Mitchell D. Schnall
Group Co-Chair, ECOG-ACRIN Cancer Research Group; Chair of Radiology, University of Pennsylvania
ImagingBreast MRIImaging trials
Mitchell Schnall is the radiologist who brought imaging research into the ECOG-ACRIN cooperative group.
Peter J. O'Dwyer
Group Co-Chair, ECOG-ACRIN Cancer Research Group; Professor of Medicine, University of Pennsylvania
Gastrointestinal oncologyDrug developmentCooperative group trials
Peter O'Dwyer is a GI oncologist who co-leads ECOG-ACRIN, one of the NCI's national trial networks.
Shaji K. Kumar
Professor of Medicine; Chair, Myeloma, Amyloidosis and Dysproteinemia Group, Mayo Clinic
Multiple myelomaClinical trialsMRD
Myeloma trialist who led venetoclax and quadruplet studies and helped define MRD response criteria.
Notes
top- NCTN cooperative group
- E1910 blinatumomab
- TMIST screening trial
- Imaging biomarker trials
rctNew England Journal of Medicine 2024changed practice222 citations
ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission
E1910 changed the standard of care for adult B-ALL: immunotherapy is now part of front-line consolidation even for patients with no detectable leukaemia, because MRD-negative by flow cytometry does not mean cured. It also demonstrated that a T-cell engager can improve overall survival in a curative setting. Chemotherapy-light or chemotherapy-free regimens built on blinatumomab and inotuzumab are the next step.
rctNew England Journal of Medicine 2006changed practice4,274 citations
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
The first time a targeted biological agent extended survival in lung cancer, and the first time median survival in the advanced setting crossed twelve months. It also set the pattern that a drug's exclusion criteria can matter as much as its mechanism.
rctNew England Journal of Medicine 2002changed practice3,886 citations
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
The ceiling of undirected cytotoxic chemotherapy, measured precisely. Everything that came afterwards, from histology-directed pemetrexed to EGFR inhibitors to checkpoint blockade, is an attempt to break a plateau this trial demonstrated could not be broken by changing the drugs.
Similar pages
- CompanySWOG Cancer Research Network
Shares A publicly held library of investigational drugs available for academic combination trials, Follow every trial participant for 30 years through registry linkage, A fixed share of trial-group funding for getting proven care to patients, ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) and the tag cooperative-group.
- CompanyAlliance for Clinical Trials in Oncology
Shares I-SPY 1 (CALGB 150007/150012, ACRIN 6657), ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials), Lung-MAP (SWOG S1400 and S1900), Older and multimorbid patients are excluded and undertreated and the tag cooperative-group.
- CompanyNRG Oncology
Shares ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials), Lung-MAP (SWOG S1400 and S1900), Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Trials enrol too few, too slowly and the tag cooperative-group.
- CompanyChildren's Oncology Group (COG)
Shares Follow every trial participant for 30 years through registry linkage, University of Wisconsin Carbone Cancer Center, Blinatumomab, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on and the tag cooperative-group.
- CompanyCanadian Cancer Trials Group (CCTG)
Shares A publicly held library of investigational drugs available for academic combination trials, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Trials enrol too few, too slowly and the tag cooperative-group.
- CompanyGIMEMA
Shares Blinatumomab, Acute lymphoblastic leukaemia and the tag cooperative-group.
- CompanyEORTC
Shares A fixed share of trial-group funding for getting proven care to patients, Secrecy and intellectual property block collaboration and the tag cooperative-group.
- CompanyUNICANCER
Shares A publicly held library of investigational drugs available for academic combination trials, Trials enrol too few, too slowly and the tag cooperative-group.
cancers
technologies
drugs
ApprovedBispecific T-cell engager (CD19×CD3)
Blinatumomab · Blincyto
EstablishedOral cytotoxic regimen
institutions
trials
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)Bleomycin, Doxycycline, or Talc in Treating Patients With Malignant Pleural EffusionsCHAARTED (E3805)ComboMATCH (EAY191)DREAMseq (ECOG-ACRIN EA6134)EA2197 ivonescimab: ivonescimab with gemcitabine and cisplatin versus standard chemo-immunotherapy in advanced biliary tract cancerECOG-ACRIN E1910ECOG-ACRIN E3311ECOG-ACRIN EA1131Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate CancerI-SPY 1 (CALGB 150007/150012, ACRIN 6657)InPACTInterAACTLung-MAP (SWOG S1400 and S1900)NCI-MATCH (EAY131)OPT-IN (EA2197)STAMP (EA6174)TAILORxTesting Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP TrialTMIST (Tomosynthesis Mammographic Imaging Screening Trial)Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
roadmaps
ideas
A fixed share of trial-group funding for getting proven care to patientsA national platform trial that every ctDNA-positive patient can joinA publicly held library of investigational drugs available for academic combination trialsChemotherapy before the second operation for high-risk incidental gallbladder cancerFollow every trial participant for 30 years through registry linkage